Synapse

← Sophia Zoungas

Papers by Sophia Zoungas

Page 1 · newest first

  1. Cardiovascular risk, evaluation and management in patients with hypertriglyceridaemia: a Consensus Statement from the International Atherosclerosis SocietyNature Reviews Cardiology · 2026
  2. Classifying lipid lowering intensity in the era of combination therapy: A proposal to define very high intensity regimensEuropean Journal of Preventive Cardiology · 2026
  3. Statin use and depression in older adults: a target trial emulation with implication for prevention and long-term managementJournal of Affective Disorders · 2026
  4. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.2026
  5. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysisEuropean Journal of Preventive Cardiology · 2026
  6. Opioid Use Is Associated With Lower Health‐Related Quality of Life Among Community‐Dwelling Older Australians: A Cross‐Sectional Study From STAREEJournal of the American Geriatrics Society · 2026
  7. Atorvastatin, Cardiovascular Events, and Disability-free Survival in Older AdultsNew England Journal of Medicine · 2026
  8. Beyond Health Outcomes: Broader Societal Impacts in Economic Evaluations of Type 1 Diabetes TechnologiesDiabetes Care · 2026
  9. Population genomic screening of young adults for familial hypercholesterolaemia: a cost-effectiveness analysisEuropean Heart Journal · 2021
  10. Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older AdultsJournal of the American College of Cardiology · 2021
  11. Baseline Computed Tomography Coronary Angiography and Polygenic Risk Profiles in Adults With Type 2 Diabetes: A Cross‐Sectional Analysis From the VOLTAIRE StudyDiabetes Obesity and Metabolism · 2026
  12. Shifts in Incident Glucose Lowering Drug Initiation in Type 2 Diabetes From 2014 to 2024: A Population‐Based StudyDiabetes Obesity and Metabolism · 2026
  13. Evaluation of Polygenic Scores and CT Imaging in Risk Factor Modification in Patients With Diabetes: Rationale and Design of the VOLTAIRE StudyClinical Cardiology · 2026
  14. Beta-blocker therapy after myocardial infarction: an umbrella reviewEClinicalMedicine · 2026
  15. Aspirin Is Beneficial in Hypertensive Patients With Chronic Kidney DiseaseJournal of the American College of Cardiology · 2010
  16. Geographic Variation in Loneliness and Social Isolation in Australia: Socio-Demographic and Healthcare Utilisation DeterminantsHealthcare · 2026
  17. Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With DiabetesJournal of the American College of Cardiology · 2022
  18. Aortic Pulse Wave Velocity Improves Cardiovascular Event PredictionJournal of the American College of Cardiology · 2013
  19. Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWINDDiabetes Care · 2026
  20. Beta-blocker therapy and all-cause mortality after a coronary event: A matched nested case-control study using the Victorian Cardiac Outcomes Registry linked dataCurrent Problems in Cardiology · 2026
  21. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesNew England Journal of Medicine · 2025
  22. Automated Insulin Delivery Is Associated with Reduced Hospital Admissions and Costs for Acute Diabetes Complications in Children with Type 1 DiabetesDiabetes Technology & Therapeutics · 2025
  23. Medication Use in Type 1 Diabetes and the Association with Socioeconomic Disadvantage: Analysis of a National Linked DatasetDiabetes Technology & Therapeutics · 2025
  24. Adherence patterns to cardiovascular medications in people with type 2 diabetes mellitus: a retrospective cohort study using group-based trajectory analysis in primary careDiabetes Research and Clinical Practice · 2025
  25. Global challenges in diabetes research and care: which way forward? An appraisal from the EASD Global CouncilDiabetologia · 2025
  26. Statistical analysis plan for the STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER) study: a randomised, open label, controlled trial in subjects with persistent neurological symptoms after COVID-19 infection2025
  27. Genomic risk prediction for type 2 diabetes in Australian individuals aged 70 years and olderDiabetes Obesity and Metabolism · 2025
  28. The association of weight status with glycemic control, diabetes related complications and anti-hyperglycemic medication use in patients with type 2 diabetes mellitus: The results of the Australian National Diabetes Audit (ANDA) 2015–2022Diabetes Research and Clinical Practice · 2025
  29. Kidney Disease: Improving Global Outcomes Summit Recommendations on Implementation of Diabetes Management in CKD: From Primary to Data-Driven Collaborative CareKidney International Reports · 2025
  30. STAREE-HEART: A randomized placebo-controlled trial of atorvastatin effects on a marker of cardiac aging in older individuals without prior cardiovascular disease events: Protocol and baseline description of participantsAmerican Heart Journal · 2025
  31. Diabetes distress screening using PAID‐5 and PAID‐1 among adults attending a tertiary multidisciplinary type 1 diabetes clinicDiabetic Medicine · 2025
  32. Kidney Disease: The Forgotten Legacy of Type 1 DiabetesDiabetes Care · 2025
  33. Performance of the American Heart Association PREVENT Cardiovascular Risk Equations in Older AdultsCirculation Cardiovascular Quality and Outcomes · 2025
  34. STatin TReatment for COVID-19 to Optimise NeuroloGical recovERy (STRONGER): study protocol for a randomised, open label clinical trial in patients with persistent neurological symptoms after COVID-19 infectionBMJ Open · 2025
  35. Building a professionally recognised clinical trial workforce: Is it time for an education and accreditation strategy?Clinical Trials · 2025
  36. A randomised clinical trial of STAtin therapy for Reducing Events in the Elderly (STAREE): Statistical analysis plan2025
  37. Rethinking cardiovascular prevention: cost-effective cholesterol lowering for statin-intolerant patients in Australia and the UKEuropean Journal of Preventive Cardiology · 2025
  38. Beta-Blocker Therapy After Myocardial InfarctionJACC Advances · 2025
  39. Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older AdultsNeurology · 2025
  40. Cardiovascular effects of tirzepatideJournal of Endocrinology · 2025
  41. Effects of statins on kidney function in older adultsJournal of the American Geriatrics Society · 2024
  42. Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE TrialDiabetes Care · 2024
  43. Baseline Characteristics of Participants in STAREE: A Randomized Trial for Primary Prevention of Cardiovascular Disease Events and Prolongation of Disability‐Free Survival in Older PeopleJournal of the American Heart Association · 2024
  44. Impact of genetic risk information for cardiovascular disease on behavioural changes, psychological responses and risk factor modification: a systematic reviewEuropean Journal of Preventive Cardiology · 2024
  45. Hypoglycaemia Prevention, Awareness of Symptoms, and Treatment (HypoPAST): protocol for a 24-week hybrid type 1 randomised controlled trial of a fully online psycho-educational programme for adults with type 1 diabetesTrials · 2024
  46. Polygenic risk, aspirin, and primary prevention of coronary artery diseaseEuropean Heart Journal - Cardiovascular Pharmacotherapy · 2024
  47. The impact of sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on insulin utilisation and costs in Australia: a national retrospective observational cross-sectional studyThe Lancet Regional Health - Western Pacific · 2024
  48. Do clinical decision support tools improve quality of care outcomes in the primary prevention of cardiovascular disease: A systematic review and meta-analysisAmerican Journal of Preventive Cardiology · 2024
  49. Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023Diabetes Obesity and Metabolism · 2024
  50. The cost-effectiveness of semaglutide in reducing cardiovascular risk among people with overweight and obesity and existing cardiovascular disease, but without diabetesEuropean Heart Journal - Quality of Care and Clinical Outcomes · 2024